IMDX
Insight Molecular Diagnostics Inc.NASDAQHealthcare$3.76+9.30%ClosedMarket Cap: $100.9M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
-3.26
P/S
22.31
EV/EBITDA
-2.90
DCF Value
$-3.25
FCF Yield
-28.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
4.7%
Operating Margin
-754.1%
Net Margin
-1238.5%
ROE
684.6%
ROA
-195.0%
ROIC
-197.4%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $1.1M | -142.6% | $-2.9M | $-23.0M | $-0.75 | — |
| FY 2025 | $4.1M | 4.7% | $-30.6M | $-50.2M | $-1.65 | — |
| Q3 2025 | $260.0K | 53.5% | $-11.0M | $-10.9M | $-0.34 | — |
| Q2 2025 | $518.0K | 67.6% | $-9.8M | $-9.7M | $-0.30 | — |
| Q1 2025 | $2.1M | 62.0% | $-6.8M | $-6.7M | $-0.26 | — |
| Q4 2024 | $1.5M | 40.0% | $-33.6M | $-33.5M | $-1.93 | — |
| FY 2024 | $1.9M | 39.3% | $-61.0M | $-60.7M | $-4.66 | — |
| Q3 2024 | $115.0K | 43.5% | $-13.5M | $-13.5M | $-0.98 | — |
| Q2 2024 | $104.0K | 48.1% | $-4.6M | $-4.5M | $-0.36 | — |
| Q1 2024 | $176.0K | 25.6% | $-9.3M | $-9.1M | $-1.13 | — |
| Q4 2023 | $314.0K | -30.3% | $-16.2M | $-16.0M | $-1.96 | — |
| FY 2023 | $1.5M | 27.5% | $-25.1M | $-27.8M | $-3.75 | — |